Brief: Valeo Pharma Signs Licensing Agreement With Pharmamar To Commercialize Yondelis In Canada
21/01/2020 12:04
Jan 21 (Reuters) - Valeo Pharma Inc VPH.CD :
* VALEO PHARMA SIGNS LICENSING AGREEMENT WITH PHARMAMAR TO
COMMERCIALIZE YONDELIS® IN CANADA
* VALEO PHARMA INC - YONDELIS SALES TO START CONTRIBUTING TO
VALEO'S REVENUES IN SECOND HALF OF 2020
* VALEO PHARMA INC - UNDER TERMS OF AGREEMENT, VALEO SHALL
PAY A
ONE-TIME LICENCE PAYMENT TO PHARMAMAR
* VALEO PHARMA - PHARMAMAR WILL RETAIN EXCLUSIVE PRODUCTION
RIGHTS
AND WILL SELL PRODUCT TO VALEO FOR COMMERCIAL USE, IN DEAL
Source text for Eikon: ID:nCNWpjf8Ta
Further company coverage: VPH.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Valeo Pharma
See all newsBrief: Valeo Pharma Says Co Initiates Restructuring Proceedings
Brief: Valeo Pharma Amends Credit Facility With Sagard Healthcare Royalty Partners
Brief: Valeo Pharma Announces Restructuring Of Commercial Field Operations To Support Path To Profitability
Brief: Valeo Pharma Announces Appointment Of Mr. Al Moghaddam To Board Of Directors
Brief: Valeo Pharma Amends Agreement With Novartis Pharmaceuticals Canada